Cleaved LC3A Antibody Blocking peptide
€363.00
In stock
SKU
AC-BP1805a
Background:
Autophagy is a process of intracellular bulk degradation in which cytoplasmic components including organelles are sequestered within double-membrane vesicles that deliver the contents to the lysosome/vacuole for degradation. There are three primary forms of autophagy: chaperone-mediated autophagy, microautophagy and macroautophagy. During macroautophagy, the sequestering vesicles, termed autophagosomes, fuse with the lysosome or vacuole resulting in the delivery of an inner vesicle (autophagic body) into the lumen of the degradative compartment. There are 16 proteins participating in autophagy pathway in human (http://ca.expasy.org/cgi-bin/get-entries? KW=Autophagy&view=tree). Abgent?s exclusive product line for autophagy research, 2-4 epitopes for each protein, provides antibodies against each protein in the pathway.
Other Names:
Microtubule-associated proteins 1A/1B light chain 3A, Autophagy-related protein LC3 A, Autophagy-related ubiquitin-like modifier LC3 A, MAP1 light chain 3-like protein 1, MAP1A/MAP1B light chain 3 A, MAP1A/MAP1B LC3 A, Microtubule-associated protein 1 light chain 3 alpha, MAP1LC3A
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1805a was selected from the C-terminal cleavage site of human cleaved-LC3 (APG8a). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: MAP1LC3A
Gene ID: 84557
Primary Accession: Q9H492
Other Accession: Q5JWU0
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Autophagy is a process of intracellular bulk degradation in which cytoplasmic components including organelles are sequestered within double-membrane vesicles that deliver the contents to the lysosome/vacuole for degradation. There are three primary forms of autophagy: chaperone-mediated autophagy, microautophagy and macroautophagy. During macroautophagy, the sequestering vesicles, termed autophagosomes, fuse with the lysosome or vacuole resulting in the delivery of an inner vesicle (autophagic body) into the lumen of the degradative compartment. There are 16 proteins participating in autophagy pathway in human (http://ca.expasy.org/cgi-bin/get-entries? KW=Autophagy&view=tree). Abgent?s exclusive product line for autophagy research, 2-4 epitopes for each protein, provides antibodies against each protein in the pathway.
Other Names:
Microtubule-associated proteins 1A/1B light chain 3A, Autophagy-related protein LC3 A, Autophagy-related ubiquitin-like modifier LC3 A, MAP1 light chain 3-like protein 1, MAP1A/MAP1B light chain 3 A, MAP1A/MAP1B LC3 A, Microtubule-associated protein 1 light chain 3 alpha, MAP1LC3A
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1805a was selected from the C-terminal cleavage site of human cleaved-LC3 (APG8a). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: MAP1LC3A
Gene ID: 84557
Primary Accession: Q9H492
Other Accession: Q5JWU0
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review